Quest for the right Drug
קרבדקסון 12.5 CARVEDEXXON 12.5 (CARVEDILOL)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects (a) Summary of the safety profile The frequency of adverse reactions is not dose-dependent except for dizziness, visual disturbances and bradycardia. (b) Table of adverse reactions The risk of most adverse reactions associated with carvedilol is similar for all indications. The exceptions are described in subsection (c). The following undesirable effects have been reported (e.g., from clinical trials, post- authorisation safety studies or spontaneous reporting) to occur when carvedilol is administered: Frequency categories are as follows: Very common ≥1/10 Common ≥1/100 to <1/10 Uncommon ≥1/1,000 to <1/100 Rare ≥1/10,000 to <1/1,000 Very rare <1/10,000 Table 1: Adverse Reactions System Organ Class Adverse Reaction Frequency Infections and infestations Pneumonia Common Bronchitis Common Upper respiratory tract infection Common Urinary tract infection Common Blood and lymphatic system Anaemia Common disorders Thrombocytopenia Rare Leukopenia Very rare Immune system disorders Hypersensitivity (allergic reactions) Very rare Metabolism and nutrition Weight increase Common disorders Hypercholesterolaemia Common Impaired blood glucose control Common (hyperglycaemia, hypoglycaemia) in patients with pre-existing diabetes Psychiatric disorders Depression, depressed mood Common Sleep disorders Uncommon Nervous system disorders Dizziness Very common Headache Very common Syncope, presyncope Common Paraesthesia Uncommon Eye disorders Visual impairment Common Lacrimation decreased (dry eye) Common Eye irritation Common Cardiac disorders Cardiac failure Very common Bradycardia Common Hypervolaemia (fluid overload) Common Atrioventricular block Uncommon Angina pectoris Uncommon Vascular disorders Hypotension Very common Orthostatic hypotension Common Disturbances of peripheral circulation Common (cold extremities, peripheral vascular disease, exacerbation of intermittent claudication and Raynaud's phenomenon) Hypertension Common Respiratory, thoracic and Dyspnoea Common mediastinal disorders Pulmonary oedema Common Asthma in predisposed patients Common Nasal congestion, flu-like symptoms Rare Gastrointestinal Disorders Nausea Common Diarrhoea Common Vomiting Common Dyspepsia Common Abdominal pain Common Constipation Uncommon Dry mouth Rare Hepatobiliary disorders Alanine aminotransferase (ALT), aspartate Very rare aminotransferase (AST) and gamma- glutamyltransferase (GGT) increased Skin and subcutaneous Skin reactions (e.g., allergic exanthema, Uncommon disorders dermatitis, urticaria, pruritus, psoriatic and lichen planus like skin lesions), alopecia Musculoskeletal and Pain in extremities Common connective tissue disorders Renal and urinary disorders Renal failure and renal function Common abnormalities in patients with diffuse vascular disease and/or underlying renal insufficiency Micturition disorders Rare Urinary incontinence in women Very rare Reproductive system and Erectile dysfunction Uncommon breast disorders General disorders and Asthenia (fatigue) Very common administration site Oedema Common conditions Pain Common (c) Description of selected adverse reactions The frequency of adverse reactions is not dose-dependent, with the exception of dizziness, abnormal vision and bradycardia. Dizziness, syncope, headache and asthenia are usually mild and are more likely to occur at the beginning of treatment. In congestive heart failure patients, worsening cardiac failure and fluid retention may occur during up-titration of carvedilol dose (see section 4.4). Cardiac failure was a very commonly reported adverse event in both placebo (14.5%) and carvedilol-treated (15.4%) patients, in patients with left ventricular dysfunction following acute myocardial infarction. Reversible deterioration of renal function has been observed with carvedilol therapy in chronic heart failure patients with low blood pressure, ischaemic heart disease and diffuse vascular disease and/or underlying renal insufficiency (see section 4.4). The following adverse events have been identified during post-marketing use of carvedilol. Because these events are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency and/or establish a causal relationship to medicine exposure: Metabolism and nutrition disorders As a class, beta-adrenergic receptor blockers may cause latent diabetes to become manifest, manifest diabetes to be aggravated, and blood glucose counter-regulation to be inhibited. Psychiatric disorders Carvedilol may cause hallucinations. Cardiac disorders Sinus arrest may occur in predisposed patients (e.g., elderly patients or patients with pre- existing bradycardia, sinus node dysfunction or atrioventricular block). Skin and subcutaneous tissue disorders Severe cutaneous adverse reactions (Toxic epidermal necrolysis, Stevens-Johnson syndrome (see section 4.4). Hyperhidrosis. Renal and urinary disorders Carvedilol may cause urinary incontinence in women which resolves upon discontinuation of the medication. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/2000
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף
עלון מידע לצרכן
21.11.22 - עלון לצרכן אנגלית 07.11.17 - עלון לצרכן עברית 21.11.22 - עלון לצרכן ערבית 21.11.22 - עלון לצרכן עברית 08.05.23 - עלון לצרכן אנגלית 08.05.23 - עלון לצרכן עברית 08.05.23 - עלון לצרכן ערבית 15.11.23 - עלון לצרכן עברית 17.05.24 - עלון לצרכן אנגלית 17.05.24 - עלון לצרכן עברית 17.05.24 - עלון לצרכן ערבית 12.08.12 - החמרה לעלון 27.03.17 - החמרה לעלון 14.11.22 - החמרה לעלון 08.05.23 - החמרה לעלון 15.11.23 - החמרה לעלוןלתרופה במאגר משרד הבריאות
קרבדקסון 12.5